Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL

Name: Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL
License: Public Domain

City of Hope Medical Center

ClinicalTrials.gov · Datasets · License: Public Domain

Open Source ↗

recurrent hodgkin lymphoma, refractory hodgkin lymphoma

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 444882
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.